Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Oct;8(5):402-10.
doi: 10.3816/CBC.2008.n.048.

Evolution of bevacizumab-based therapy in the management of breast cancer

Jasgit C Sachdev  1 , Mohammad Jahanzeb
Affiliations
Review

Evolution of bevacizumab-based therapy in the management of breast cancer

Jasgit C Sachdev et al. Clin Breast Cancer. 2008 Oct.

Abstract

Combination therapy comprising bevacizumab with paclitaxel recently received accelerated approval from the US Food and Drug Administration (FDA) for use in the first-line treatment of patients with metastatic breast cancer. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), providing direct inhibition of angiogenesis. The evolution of bevacizumab use in the first-line treatment of patients with breast cancer has been characterized by a logical progression of phase II and III trials that have demonstrated that angiogenesis plays an important role throughout all stages of breast cancer growth and progression. In the phase III clinical trial E2100, which provided the basis for FDA approval, the use of bevacizumab (10 mg/kg on days 1 and 15) plus paclitaxel (90 mg/m2 days 1, 8, and 15 every 28 days) given until disease progression approximately doubled median progression-free survival (PFS; 11.8 months vs. 5.9 months; hazard ratio = 0.60; P < .001) compared with paclitaxel alone; by contrast, a statistically significant improvement in overall survival was not seen with the addition of bevacizumab, although a post hoc analysis demonstrated a significant increase in 1-year survival for the combination arm. The E2100 study, as well as the majority of clinical trial designs for bevacizumab, has used PFS as the primary efficacy endpoint, and, in this review, the development of PFS as a measure of clinical benefit is outlined. This review also discusses the importance of VEGF signaling in early phases of breast tumor progression, which has provided a rationale for the investigation of bevacizumab in early-stage settings.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles